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Abstract
Inflammation is a hallmark of many diseases. Although steroids and cyclooxygenase inhibitors are main anti-inflammatory
therapeutical agents, they may cause serious side effects. Therefore, developing non-steroid anti-inflammatory agents is
urgently needed. A novel hydrosoluble compound, C12 (2,6-bis(4-(3-(dimethylamino)-propoxy)benzylidene)cyclohexanone),
has been designed and synthesized as an anti-inflammatory agent in our previous study. In the present study, we
investigated whether C12 can affect inflammatory processes in vitro and in vivo. In mouse primary peritoneal macrophages,
C12 potently inhibited the production of the proinflammatory gene expression including TNF-a, IL-1b, IL-6, iNOS, COX-2 and
PGE synthase. The activity of C12 was partly dependent on inhibition of ERK/JNK (but p38) phosphorylation and NF-kB
activation. In vivo, C12 suppressed proinflammatory cytokine production in plasma and liver, attenuated lung
histopathology, and significantly reduced mortality in endotoxemic mice. In addition, the pre-treatment with C12 reduced
the inflammatory pain in the acetic acid and formalin models and reduced the carrageenan-induced paw oedema and
acetic acid-increased vascular permeability. Taken together, C12 has multiple anti-inflammatory effects. These findings,
coupled with the low toxicity and hydrosolubility of C12, suggests that this agent may be useful in the treatment of
inflammatory diseases.
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Introduction
Inflammation is a complex biological response. A number of
reports have suggested that a chronic or acute inflammatory state
is tightly associated with, and even constitutes a crucial part of the
pathogenesis of a variety of diseases, including atherosclerosis [1],
diabetic complications [2], obstructive pulmonary disease [3],
asthma [4], arthritis [5], infectious diseases [6], and cancer [7]. In
inflammatory diseases and ischemic processes, large amounts of
cytokines are produced causing oedema, cellular metabolic stress,
and finally, tissue necrosis [8]. Cytokines also induce vasodilatation
and transient increase in capillary permeability producing
extravasation of plasma proteins [9]. The proinflammatory
cytokines tumor necrosis factor (TNF)-a, interleukin (IL)-1, and
IL-6, and the proinflammatory enzymes cycloxygenase (COX)-2,
prostaglandin E synthase (PGES) and inducible NO synthase
(iNOS) which produce hormone-like mediators such as NO, are
primarily involved in promoting inflammatory processes, and they
also play an important role in those disorders [10,11].
Steroids and cyclooxygenase inhibitors have long been used as
the main therapeutic anti-inflammatory agents, but they are
frequently associated with significant detrimental effects in patients
[12,13]. Thus, there is an urgent need for the development of
unique anti-inflammatory agents. Non-steroid anti-inflammatory
candidates targeting proinflammatory cytokines or inhibiting the
overexpression of cytokines become a major focus of current drug
development [14]. Our previous study has demonstrated that a
novel compound, 2,6-bis(4-(3-(dimethylamino)-propoxy)benzylide-
ne)cyclohexanone (C12), is able to dose-dependently inhibit LPS-
induced TNF-a and IL-6 release in RAW264.7 macrophages [15].
In addition, C12 is a hydrosoluble compound when combined
with HCl to form a quaternary ammonium salt. These in vitro
advantages render C12 as a potential anti-inflammatory agent.
The aim of the present work is to evaluate the anti-inflammatory
effects of C12 and investigate its pharmacological mechanism in
macrophages and mouse models. Herein, we showed that C12
inhibited ERK/JNK and NF-kB dependent inflammatory re-
sponses in vitro. The anti-inflammatory effects of C12 contribute to
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24377its increase of survival and multi-organic protection from
endotoxin shock in vivo. These studies thus identify C12 as a
unique anti-inflammatory agent that may be positioned as a
therapeutic agent for the treatment of inflammatory diseases.
Results
C12 inhibited LPS-induced NO production in mouse
peritoneal macrophages (MPMs)
Previously, we demonstrated that C12 was able to inhibit LPS-
induced TNF-a and IL-6 release in a dose-dependent manner in
RAW264.7 macrophages [15]. Due to the importance of NO as
an inflammatory mediator on inflammation-related physiological
and pathological processes [10], we tested the effect of C12 on the
nitrite level, an index of NO production, in MPMs stimulated with
LPS (1 mg/mL). As shown in Figure 1B, C12 dose-dependently
repressed LPS-induced increase in nitrite after 18-hour incubation.
C12 treatment at 10 mM reduced nitrite level by 45% compared to
the LPS-challenged group (p,0.01).
C12 suppressed LPS-induced proinflammatory gene
expression in MPMs
MPMs were treated with LPS (0.5 mg/mL) for 6 h and examined
for the expression of proinflammatory genes in the presence or
absence of C12 by real-time quantitative PCR. In the dose-
dependent study in our previous work [15], C12 at 2.5 uM
exhibited an inhibition of 77.4% against LPS-induced IL-6
expression and an inhibition of 40.3% against TNF-a in
macrophages. Therefore, we selected the concentration of 2.5 uM
for further RT-qPCR study here. As shown in Figure 2, C12 at
2.5 mM potently inhibited LPS-induced up-regulation of IL-12
(74.3%, p,0.01), IL-1b (91.5%, p,0.01), TNF-a (80.2%, p,0.01),
IL-6 (69.6%, p,0.01), and cycloxygenase-2 (COX-2, 40.7%,
p,0.05) transcripts in MPMs.
C12 inhibited LPS-induced NF-kB activation and ERK/JNK
phosphorylation
In the LPS-induced inflammatory stress, LPS-TLR4 signal
transduction leads to MyD88-dependent phosphorylation of
mitogen-activated protein kinases (MAPKs) and activation of
nuclear factor (NF)-kB, which regulate the transcription of a
variety of inflammatory factors and enzymes [16,17]. We
investigated whether C12 acts as an anti-inflammatory agent by
inhibiting NF-kB and MAPKs. We first evaluated the effect of C12
on NF-kB p65 nuclear translocation. As shown in Figure 3A, LPS
could strengthen NF-kB p65 nuclear translocation (red point in
blue nucleus), while in C12-pretreated cells, LPS-induced nuclear
p65 decreased, suggesting that C12, at a concentration of 10 mM,
inhibited p65 translocation from cytoplasm to nuclei. IkBa
phosphorylation and degradation frees NF-kB p65 from seques-
tration, allowing it to translocate to the nucleus, bind to target
promoters, and turn-on transcription [12]. We next determined
the total IkBa and phosphorylated IkBa in total cell protein
extracts by Western blotting. LPS exposure for 1 h induced a 7.4-
fold phosphorylation (Figure 3B) and an 87% degradation of
IkBa (Figure 3C) in MPMs. Conversely, C12 at 10 mMi n h i b i t e d
LPS-induced IkBa phosphorylation (20% inhibition, Figure 3B)
and degradation (4.43-fold increase, Figure 3C) in MPMs,
respectively.
ERK, p38, and JNK constitute the MAPK family and are
important intracellular components of the inflammatory responses
to LPS. Especially, phosphorylated JNK and ERK could activate
NF-kB signaling by IKKa/b-mediated IkBa phosphorylation and
degradation [12,16,17]. Therefore, we tested whether the anti-
inflammatory effect of C12 is due to its interference with these
pathways. Figure 3D–3F shows that all of three MAPKs were
activated by LPS stimulation. Among these kinases, the LPS-
induced phosphorylation of ERK and JNK were significantly
attenuated by pretreatment with C12 (10 mM). However, C12 did
not decrease the amount of phosphorylated p38. Although C12
inhibits LPS-induced ERK phosphorylation in MPMs, it is
unknown whether the ERK pathway is required for the inhibitory
effects of C12 on proinflammatory responses. To this end, we
utilized PD98059, a specific p-ERK inhibitor, to suppress the
cellular ERK pathway activity. In the presence of PD98059, the
inhibition of LPS-induced TNF-a release by C12 were signifi-
cantly abrogated in MPMs (p,0.05, Figure 3G). These results
imply that NF-kB activation and ERK phosphorylation might be
an important step in mediating the anti-inflammatory effects of
C12 in macrophages.
C12 inhibited the increases of serum TNF-a, IL-6 and NO
levels in LPS-challenged mice
C12 was further evaluated its anti-inflammatory benefits in
animals. Given the in vitro results and in vivo toxicity test in (Figure
S1), mice were administered with C12 at 15 mg/kg (i.p.) or 10 and
30 mg/kg (i.v.) in the following in vivo experiments (Text S1). The
serum levels of TNF-a, IL-6 and NO can reflect the degree of
Figure 1. The structure and NO-inhibitory activity of C12. A. Chemical structures of C12 and its water-soluble form C12-HCl; B. C12 inhibitd
nitrite production. MPMs were pretreated with vehicle (H2O) or C12 (2.5, 5, and 10 mM) for 2 h and then stimulated with 1 mg/mL LPS for 18 h. The
nitrite levels in medium were detected as described in Materials and Methods. Bars represent the mean6SD of three independent experiments
performed in duplicate, and asterisks indicate significant inhibition (* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0024377.g001
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anti-inflammatory effect of C12, C57B/L6 (B6) mice administered
with LPS (10 mg/kg, i.v.) and C12 (15 mg/kg, i.v.) were sacrificed
and the plasma levels of inflammatory mediators were determined
by ELISA. The plasma levels of TNF-a, IL-6 and NO increased
over the 1–12 h period after LPS injection, and reached peak at
1 h (TNF-a), 6 h (IL-6) and 6 h (NO), respectively (data not
shown). Pretreatment with C12 showed a 71.5% (n=6, p,0.01)
inhibition on TNF-a levels and a 53.0% (n=6, p,0.05) inhibition
on IL-6 levels compared to the LPS group (Figure 4A and 4B).
Plasma nitrite level also increased at 6 h after LPS administration
and pretreatment with C12-inhibited LPS-mediated NO produc-
tion by 44.8% (Figure 4C, statistically non-significant between
C12+LPS group vs. LPS group).
Figure 2. C12 inhibited LPS-induced inflammatory mRNA expression in MPMs. Cells were pretreated with compounds at 2.5 mM or vehicle
(H2O) control for 2 h and treated with LPS (0.5 mg/mL) for 6 h. The mRNA levels of inflammatory cytokines IL-12, IL-1b, TNF-a, IL-6 and COX-2 were
quantified by real-time quantitative PCR. The mRNA value was normalized to internal control b-actin mRNA and was expressed as a ratio to H2O. Bars
represent the mean6SD of three independent experiments (* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0024377.g002
Figure 3. C12 inhibited LPS–induced NF-kB activation and MAPK phosphorylation. A. Cultured MPMs were pretreated with vehicle (H2O)
or 10 mM C12 for 2 h and then stimulated with 0.5 mg/mL LPS. After 1 h of treatment, the cells were incubated with p65 antibody and Cy3
fluorescein-conjugated secondary antibody, and nuclei were stained with DAPI. The images (2006) were obtained by fluorescence microscope and
overlay. Similar results were obtained with five independent experiments. B–F. MPMs were pretreated with vehicle (H2O) or C12 (10 mM) for 2 h
followed by incubation with LPS (0.5 mg/mL) for 1 h. The protein levels of p-IkBa,I kBa, p-ERK, ERK, p-JNK, JNK, p-p38, and p38 were examined by
western blot with actin as a loading control (values on the top of western blots represent the mean optical density ratio in three independent
experiments, * p,0.05, ** p,0.01, vs LPS group). G. MPMs were pretreated with vehicle (H2O) or C12 (5 mM) for 2 h, and then stimulated with 0.5 mg/
mL LPS for 12 h in the absence or presence of PD98059 (20 mM). The TNF-a level in medium were detected by ELISA as described in Materials and
Methods. TNF-a expression is reported as the fold-expression relative to the LPS-treated group (n=3, * p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0024377.g003
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expression in mouse liver after LPS challenge
Real-time qPCR was used to verify the profiles of selected genes
TNF-a, IL-1b, IL-6, COX-2, iNOS and mPGES that were
involved in inflammatory response in mouse liver after LPS
challenge. A dose of LPS (10 mg/kg, i.v.) and C12 (15 mg/kg, i.v.)
was chosen for these studies. The mRNA levels of these six genes
in the liver were significantly induced by LPS administration,
while they peaked at different time points (1 to 6 h), respectively
(data not shown). TNF-a, IL-1b, and IL-6 were determined at 1 h,
3 h and 6 h after LPS injection, respectively. As illustrated in
Figure 5, the hepatic mRNA expression of TNF-a, IL-1b, IL-6,
Figure 4. Inhibition of plasma TNF-a (A), IL-6 (B) and NO (C) by C12 in LPS-injected mice. C12 (15 mg/kg, i.v.) was given to B6 mice 15 min
before LPS (10 mg/kg, i.v.) administration. Mice were killed and blood samples were collected 1 or 6 h after administration of LPS. Plasma TNF-a, IL-6
and NO concentrations were measured as described in Materials and Methods. Data point represent the mean6SD (n=6). (* p,0.05, ** p,0.01, vs
LPS group).
doi:10.1371/journal.pone.0024377.g004
Figure 5. Inhibitory effects of C12 pretreatment (15 mg/kg, i.v., 15 min before LPS injection) on the induction of inflammatory gene
mRNAs in B6 mouse livers 1 or 6 h after LPS administration (10 mg/kg, i.v.). Liver mRNA from vehicle control, LPS, and LPS+C12-treated
mice was reverse transcribed for quantitative real-time PCR analysis of the expression of TNF-a, IL-6, IL-1b, COX-2, iNOS, and PGES. Expression is
normalized to actin and reported as the fold-expression relative to one of samples in the vehicle control group. Values shown are the mean 6 SD of 3
mice from the saline control group (white), and 4–6 mice each from the LPS (black)- and LPS+C12 (yellow)- treated groups. (* p,0.1, ** p,0.05,
compared to LPS group).
doi:10.1371/journal.pone.0024377.g005
C12 Exerts Anti-Inflammatory Effects
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24377COX-2, iNOS and mPGES was suppressed (59.6%, 36.6%,
83.8%, 87.5%, 72.8% and 54.1% inhibition, p,0.05 or p,0.01,
respectively) in C12-pretreated mice compared with LPS-treated
group. These results suggested that C12 significantly inhibits the
LPS-induced increase of hepatic inflammatory gene transcription.
Effects of C12 pretreatment on lung histology in mice
after LPS administration
Acute lung injury (ALI) is one of the most sensitive responses to
LPS injection and ultimately leads to alveolar flooding with serum
proteins and oedema fluid [18]. After mice were administrated
LPS (10 mg/kg, i.v.), histological changes in the B6 mouse lung
such as inflammatory cell infiltration, peri-vascular oedema, and
marked alveolar hemorrhage, were observed by H&E staining.
C12 pretreatment at 15 mg/kg improved such pulmonary damage
remarkably (Figure 6A). C12 also amended the LPS-injured tissue
structure of pulmonary lobules and LPS-induced expansion of
lung alveolus.
C12 treatment prolonged survival in an acute
inflammatory model
To investigate the beneficial effects of C12 on acute inflamma-
tory shock, we infected B6 mice with LPS (20 mg/kg, i.v.) and
compared survival rates between C12-treated and placebo control
mice. All C12-untreated control mice had died at 48 h after LPS
injection, while all of C12-treated animals survived the acute phase
of inflammation and displayed 100% survival rates until the end of
the experiment (n=12, p,0.0001, Figure 6B). Meanwhile, the
body weight of C12-treated mice decreased during 0–48 h but
regained slowly since by 60 h after LPS treatment (Figure 6C).
Thus, C12 treatment prolongs survival in the acute inflammatory
shock model.
Treatment with C12 reduced carrageenan-induced paw
oedema and inhibited inflammation-related reactions in
chemically-induced inflammatory models
We further tested the beneficial effects of C12 on inflammation-
related models challenged by another stimulus with dexametha-
sone as a positive control. Paw oedema induced by carrageenan
has been widely used as an inflammatory model in vivo [19,20].
ICR mice were initially treated with C12 (5 and 15 mg/kg) by i.p.
injection followed by the paw oedema induced by carrageenan
(300 mg/paw) for 4 h. As shown in Figure 7A, compared to
carrageenan group, pretreatment with C12 reduced the oedema in
size in a dose-dependent way, with the inhibitory rate in oedema
size of 39.9% (5 mg/kg, p,0.01, v.s. control) and 46.9% (15 mg/
kg, p,0.01, v.s. control), respectively (Figure 7A). We also
pretreated ICR mice with C12 (5 and 15 mg/kg, i.p.) 15 min
before chemically-induced inflammatory constrictions with acetic
acid (0.6%, 200 mL, i.p.). The inflammatory pain and mice
writhing response induced by acetic acid were significantly
inhibited by C12 pretreatment in a dose-dependent manner with
inhibitory rate of 57.4% (p,0.001), and 91.6% (p,0.001),
respectively (Figure 7B). Besides inflammatory gene expression,
acetic acid-caused pain and carrageenan-caused paw oedema are
usually related to the vascular permeability increasing the release
Figure 6. Beneficial Effects of C12 against acute inflammatory injury and shock in B6 mice. A. Mice were treated with C12 (15 mg/kg, i.v.)
15 min before LPS (10 mg/kg, i.v.) administration. After 48 h, lung histopathological analysis was performed using H&E staining as described in
Materials and Methods (magnification6200; n=3; Con, control). B and C. C12 improves survival of mice subjected to a lethal dose of LPS. Mice were
pretreated with vehicle (saline) or 15 mg/kg C12 (i.v.) 15 min before the injection of 20 mg/kg of LPS (i.v.). Survival (B) and body weight (C) were
recorded for 7 days after the LPS injection at the interval of 12 h. Results from the summary of two different experiments are shown. n=12 animals in
each group. C12 improved survival rate at 12–48 h (*** p,0.0001).
doi:10.1371/journal.pone.0024377.g006
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demonstrate if C12 can reduce permeability changes during
inflammation, we performed a vascular permeability assay in ICR
mice using azovan blue and acetic acid. As shown in Figure 7C,
acetic acid increased the permeation of azovan blue from the
vascellum to abdominal cavity (4.5-fold, p,0.01), while pre-treated
with C12 can significantly reduce the OD value compared to the
acetic acid-treated group (5 mg/kg, 49%, p,0.05; 15 mg/kg,
63%, p,0.05), suggesting that C12 is able to inhibit vascular
permeability and reduce inflammatory effusion.
Moreover, the inhibitory effects of C12 on the formalin-induced
inflammatory nociception (both first and second phase) in ICR
mice were evaluated. As shown in Figure 7D, the results revealed
that i.p. pretreatment of C12 could dose-dependently reduce the
licking times of the mice stimulated by formalin, with an inhibition
of 35.3% (15 mg/kg, p,0.01) in first phase (0–10 min after
formalin injection) and an inhibition of 78.7% (15 mg/kg, p 0.001)
in second phase (15–30 min after formalin injection), respectively.
These results potently suggested that C12 is able to effectively
inhibit the in vivo inflammatory response induced by chamical
stimulus such as carrageenan, acetic acid and formalin.
Discussion
Our previous study has found that a novel compound C12
possessed inhibitory effects on LPS-induced TNF-a and IL-6
release in RAW264.7 macrophages [15]. With another advantage
of water-solubility when combined with HCl, C12 has been
considered a promising anti-inflammatory candidate. In the
present study, we demonstrated anti-inflammatory activities of
this compound both in vitro and in vivo, using LPS-stimulated
MPMs and several mouse models of topical inflammation,
respectively.
Macrophages play important roles in a host’s immune defense
system during infection as well as in the processes of disease
development [22]. Activation of macrophages by stimuli, such as
LPS, increases the production of numerous inflammatory
mediators, including various cytokines and nitric oxide (NO)
[10]. Excessive production of NO has been widely reported to be
associated with inflammatory response [23,24]. First, we showed
that C12 has a dose-dependently inhibitory activity upon NO
synthesis in MPMs (Figure 1B). Strong inhibition of inflammatory
cytokine release has been ascribed to down-regulation of NF-kB-
dependent gene transcription [25,26]. Our next experiments
provided the evidence that C12 significantly inhibits IL-12, IL-1b,
TNF-a, IL-6 and COX-2 mRNA transcription in MPMs
(Figure 2). In addition, our results shown in Figure 4 demonstrated
that C12 significantly inhibits the plasma NO level and serum
levels of TNF-a and IL-6 in LPS-stimulated mice. In response to
LPS, plasma TNF-a increased at a relatively early stage (1 h after
challenge) as a proinflammatory factor and then induced
downstream inflammatory reactions, including IL-6 and iNOS
expression (6 h after challenge) in a NF-kB-dependent manner.
Endotoxin, or more specifically LPS, is an inflammatory
stimulus that can exert effects on major organs, such as the liver.
Several groups have found that LPS could increase inflammatory
Figure 7. Effects of C12 (5 mg/kg or 15 mg/kg, i.p.) on the chemical-induced inflammatory response. A. Paw oedema models induced
by carageenan; B. acetic acid-induced pain model; C. acetic acid-vascular permeability models; D. formalin-induced nociception mice (first-
inflammatory phase, left; second-inflammatory phase, right). Control animals received saline (0.9% NaCl). Dexamethasone (5 mg/kg) was used as a
positive control. Each value represents the mean6SD of 6 animals, and asterisks indicate significant difference of the paw thickness in relation to the
corresponding saline group (* p,0.05, ** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0024377.g007
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surmised that C12 would decrease LPS-induced inflammatory
gene expression in liver. Figure 5 presented the evidence that i.v.
injection of C12 significantly reduced the mRNA levels of a host of
proinflammatory mediators (TNF-a, IL-1b, IL-6, COX-2, iNOS,
and PGES) in the LPS-challenged mouse livers. Thus, C12 is able
to decrease the production of proinflammatory mediators both in
vitro and in vivo. LPS injection further causes a whole-body
inflammatory response such as multiple organ failure (MOF),
including lung injury. The pulmonary injury is considered to be a
direct cause of death by LPS injection, and often occurred in the
context of MOF [29]. The lung histological examinations in
Figure 6A demonstrated that C12 suppressed LPS-caused severe
lung damage remarkably. LPS-induced acute multi-organ failure
ultimately causes animal death. We further confirmed that C12
would significantly decrease LPS-induced lethality. Thus, the shift
toward an anti-inflammatory cytokine profile by C12 is in
agreement with its beneficial effect in the endotoxemic shock
model.
Of particular interest in this study is the identification of
molecular mechanism by which C12 inhibits inflammatory gene
expression. LPS binds to TLR4-CD14-MD88 complex on the cell
surface to trigger MAP kinase phosphorylation and then activation
of NF-kB, a transcription factor normally sequestered in the
cytoplasm that upon stimulation translocates to the nucleus to
drive transcription of target genes, including cytokines, chemo-
kines and cellular adhesion molecules [12,16,17]). The transcrip-
tion factor NF-kB is retained in the cytoplasm in an inactive form
by the inhibitory protein IkB. Activation of NF-kB requires that
IkB be phosphorylated on serines 32 and 36, which results in
targeted degradation of IkB. The dissociation of IkB causes the
translocation of NF-kB p65 sub-unit from the cytoplasm to
nucleus. The latter binds to the DNA site and triggers the
inflammatory gene expression. Herein, we showed that C12
inhibited LPS-induced ERK/JNK phosphorylation and NF-kB
activation and the subsequent induction of proinflammatory
mediators in MPMs (Figure 3). JNK has been demonstrated as
an upstream regulator of NF-kB signal [12,16,17]. Although
MAPK pathways including ERK, p38, and JNK are all involved
in LPS-stimulated inflammation, we did not find that C12 affects
p38 activation. Furthermore, the anti-inflammatory effect of C12
was attenuated by ERK-specific inhibitor, and PD98059 also
significantly inhibited the LPS-induced TNF-a release (Figure 3G).
These results indicate that ERK critically plays a key role to turn
on proinflammatory gene expression in LPS-stimulated macro-
phages, and at least partly, C12 exerts an anti-inflammatory effect
via inhibition of ERK pathway. The partial reversion of p-ERK
inhibitor suggests that there exist ERK-independent mechanisms
in the anti-inflammatory action of C12. In the other hand, the
leading curcumin has been reported to exert anti-inflammatory
effects by multi-targeting mechanisms and the direct binding
targets of curcumin are still unknown. Therefore, although this
work only focuses on the MAPK/NF-kB-mediated inflammation,
further studies are necessary to establish such notion as
examination of the underlying molecular mechanisms and direct
molecular targets of C12.
Besides the endotoxin and etiologic agents, some chemicals also
induce the production of inflammation. During tissue inflamma-
tion, there is normally vasodilatation and transient increases in
capillary permeability producing extravasation of plasma proteins
and tissue oedema. Generally, these reactions are linked to painful
perception or hyperalgesic sensitization [19,30,31]. Our results
shown in Figure 7 indicate that pre-treatment with C12 reduced
the inflammatory pain in the acetic acid and formalin models, and
also reduced the paw oedema induced by carrageenan, and C12
can inhibit plasma substance extravasation from the blood vessel.
These inflammatory models are mainly related to local production
of bradykinin and prostaglandins, such as PGE2 and leukotrienes,
both derivatives of arachidonic acid. These prostanoids bind the
prostaglandin sub-type receptors, triggering the inflammatory and
hyperalgesic pathway in tissues. Bradykinins and related kinins
represent a group of potent inflammatory mediator peptides
involved in pain and inflammation. Bradykinin receptor B1 is
associated with a metabotropic signaling pathway producing
vasodilatation, an increase of vascular permeability, and an
increase of eicosanoids production, such as PGE2 and NO
produced by PGES, COX-2 and iNOS. On the other hand, B1
receptors promote pain stimuli and inflammation by the NF-kB
pathway [32,33]. Thus, the inhibitions of inflammatory enzyme
expression (Figure 5) and NF-kB activation (Figure 3) may mainly
contribute to these beneficial effects of C12. Of course, the results
are also partly related with the effects of C12 on inflammatory
cellular activation during the recruitment of leukocytes to an
injured target. In another inflammatory model of formalin-caused
pain, the pain in the first phase (0–10 min after formalin i.p.
injection) is induced through formalin directly stimulating C-fibers,
whereas in the second phase (15–30 min), the pain is generated by
the release of several inflammatory mediators [30,34]. Thus, the
licking times of the mice in different intervals reflect the degree of
the pain. The higher inhibitory rate of C12 in phase II than phase
I also partly indicated that the main mechanism of C12 activity is
to inhibit the production of inflammatory mediators.
Steroids and cyclooxygenase inhibitors have long been used as
major therapeutical anti-inflammatory agents. However, they
often cause serious side effects in patients [12,13,14]. Thus,
developing unique anti-inflammatory agents is currently in high
demand. C12 is a new anti-inflammatory compound designed and
synthesized in our lab. In conclusion, C12 effectively suppressed
the production of various inflammatory mediators at the levels of
both protein and mRNA by suppressing the activation of ERK/
JNK//NF-kB signaling. The evidence from in vivo studies also
supports that, with the advantages of water-solubility and low
toxicity (Figure S1 and Text S1), C12, as a non-steroidal anti-
inflammatory candidate, could provide a therapeutic option in the
treatment of topical inflammatory diseases.
Materials and Methods
Animals
Male Institute of Cancer Research (ICR) mice and C57BL/6
mice weighing 18–22 g were obtained from the Animal Center of
Wenzhou Medical College (Wenzhou, China). Animals were
housed at a constant room temperature with a 12:12 hour light-
dark cycle, and fed with a standard rodent diet and water. The
animals were acclimatized to the laboratory for at least 3 days
before use in experiments. Protocols involving the use of animals
were approved by the Wenzhou Medical College Animal Policy
and Welfare Committee (Approval documents: 2009/APWC/
0031).
Reagents
Lipopolysaccharide (LPS), carrageenan, acetic acid and forma-
lin solution were purchased from Sigma (Louis, MO). Dexameth-
asone was purchased from Xianju Pharma (Zhejiang, China).
Saline was prepared as 0.9% NaCl solution. C12 was synthesized
and characterized as described in our previous publication
[15,35]. C12 was used in the form of C12-HCl in all of the
following experiments. Briefly, C12-HCl (C12) was dissolved in
C12 Exerts Anti-Inflammatory Effects
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filters (Carrigtwohill, Co.Cork, Ireland) before use. The structures
of C12 and its chloride are shown in Figure 1.
Primary cell preparation and culture
For peritoneal macrophage preparation, ICR mice were
stimulated by intraperitoneal (i.p.) injection of 3 ml thioglycollate
solution (Beef extract (0.3 g), tryptone (1 g), sodium chloride
(0.5 g), and soluble starch (6 g) were dissolved and boiled in
100 ml water. Before used, the solution was filtrated with 0.22 mm
filter.) per mouse and kept in pathogen-free conditions for 3 days
before peritoneal macrophage isolation. Total peritoneal macro-
phages were harvested by washing the peritoneal cavity with PBS
containing 30 mM of EDTA (8 mL per mouse), centrifuged, then
the pellet was resuspended in RPMI-1640 medium (Gibco/BRL
life Technologies, Eggenstein, Germany) with 10% FBS (Hyclone,
Logan, UT), 100 U/mL penicillin, and 100 mg/mL streptomycin.
Peritoneal macrophages were cultured on 60 mm plates (1.2610
6
cells in 3 ml media per plate) and maintained at 37uCi na5 %
CO2-humidified air. Nonadherent cells were removed by washing
with medium at 3 h after seeding. Experiments were undertaken
after the cells adhered firmly to the culture plates.
Nitrite assay
A quantity of 100 mL of cell culture supernatant (or plasma in
animal experiments) was collected and combined with 50 mL1 %
sulfanilamide in 5% H3PO4 and 50 mL 0.1% N-(1-naphthyl)ethy-
lenediamine dihydrochloride (Sigma, Louis, MO) in water, in a
96-well plate, followed by spectrophotometric measurement at
550 nm, using a microplate reader. Nitrite concentration in the
supernatant was determined by comparison with a sodium nitrite
standard curve. Experiments were performed at least three times
and in duplicate.
Western Immunoblot analysis
The treated cells were collected and lysated, then 30 mg of the
whole cell lysates were separated by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and electrotransferred to a
nitrocellulose membrane. Each membrane was preincubated for
1 h at room temperature in Tris-buffered saline, pH 7.6,
containing 0.05% tween 20 and 5% non-fat milk. Each
nitrocellulose membrane was incubated with specific antibodies
against p-p38, p38, p-ERK, ERK, p-JNK, JNK (Santa Cruz, CA),
and p-IkBa,I kBa, Actin (Cell Signaling Technology, Danvers,
MA). Immunoreactive bands were then detected by incubating
with secondary antibody conjugated with horseradish peroxidase
and visualized using enhanced chemiluminescence reagents (Bio-
Rad, Hercules, CA).
Assay of cellular NF-kB p-65 translocation
The cells were immunofluorescence-labeled according to the
manufacturer’s instructions using a Cellular NF-kB p-65 Translo-
cation Kit (Beyotime Biotech, Nantong, China). Briefly, after
washing and fixing, cells were incubated with a blocking buffer for
1 htosuppressnon-specificbinding.Next,cellswereincubatedwith
the primary NF-kB p65 antibody for 1 h, followed by incubation
with a Cy3-conjugated secondary antibody for 1 h, then with DAPI
for 5 min before observation. P65 protein and nuclei fluoresce red
and blue, respectively, and can be simultaneously viewed by
fluorescence microscope (Nikon, Tokyo, Japan) at an excitation
wavelength of 350 nm for DAPI, and 540 nm for Cy3. To create a
two-color image, the red and blue images were overlaid, producing
purple fluorescence in areas of co-localization [36].
Treatment of mice with C12 and LPS
Male B6 mice weighing 18–22 g were pretreated with C12
solution (15 mg/kg) by intravenous (i.v.) injection for 15 min and
then 200 mL of LPS (10 mg/kg), dissolved in saline (0.9% NaCl),
was i.v. injected. Negative control animals received only a similar
volume (200 mL) of saline. Mice were anesthetized with diethyl
ether and sacrificed at the indicated time after LPS injection.
Blood samples were taken from the right ventricle orbital veniplex
using a heparinized syringe with a needle. Liver and plasma were
flash frozen in liquid nitrogen and stored at 280uC until analysis.
Determination of TNF-a and IL-6
After treatment of mice with C12 and LPS, the TNF-a and IL-6
levels in plasma were determined with an enzyme-linked
immunosorbent assay (ELISA) kit (Bioscience, San Diego, CA)
according to the manufacturer’s instructions. The total amount of
the inflammatory factor in the media was normalized to the total
protein quantity of the viable cell pellets.
Real-time quantitative PCR
Cells or liver tissues (50–100 mg) were homogenized in TRIZOL
(Invitrogen, Carlsbad, CA) or prepared with a PARIS kit (Ambion,
Austin, TX)for extraction of RNA according to eachmanufacturer’s
protocol. Both reverse transcription and quantitative PCR were
carried out using a two-step M-MLV Platinum SYBR Green qPCR
SuperMix-UDG kit (Invitrogen, Carlsbad, CA). Eppendorf Master-
cyclerep realplexdetection system(Eppendorf,Hamburg,Germany)
were used for q-PCR analysis. The primers of genes including iNOS,
COX-2, TNF-a, IL-6, prostaglandin synthetase (PGES), IL-1b and
b-actin were synthesized by Invitrogen. The primer sequences
used are shown as follows: mouse TNF-a sense primer: 59-TG-
GAACTGGCAGAAGAGG-39, Mouse TNF-a antisense primer:
59-AGACAGAAGAGCGTGGTG-39;mouse IL-6senseprimer:59-
GAGGATACCACTCCCAACAGACC-39, mouse IL-6 antisense
primer: 59-AAGTGCATCATCGTTGTTCATACA-39;m o u s e
COX-2 sense primer: 59-TGGTGCCTGGTCTGATGATG-39,
mouse COX-2 antisense primer: 59-GTGGTAACCGCTCAGGT-
GTTG-39; mouse PGES (mPEGS) sense primer: 59-ACACTGC-
TGGTCATCAAG-39, mouse PGES antisense primer: 59-GGTCA-
CTCCTGTAATACTGG-39; mouse iNOS sense primer: 59-
CAGCTGGGCTGTACAAACCTT-39; mouse iNOS antisense
primer: 59-CATTGGAAGTGAAGCGTTTCG-39; mouse IL-1b
sense primer: 59-ACTCCTTAGTCCTCGGCCA-39, mouse IL-1b
antisense primer: 59-CCATCAGAGGCAAGGAGGAA-39;m o u s e
b-actin sense primer: 59-TGGAATCCTGTGGCATCCAT-
GAAAC-39,m o u s eb-actin antisense primer: 59-TAAAACG-
CAGCTCAGTAACAGTCCG-39. The amount of each gene was
determined and normalized by the amount of b-actin.
Lung histopathology
Two days after LPS injection (10 mg/kg, i.v.), the lungs of B6
mice C12-pretreated (15 mg/kg, i.v.) or control were distended by
infusion of 10% formalin into the trachea at a pressure of 15 cm
H2O for 2 h, and fixed in 10% formalin for 24 h. Formalin-fixed
lungs were embedded in paraffin, sectioned and stained with
hematoxylin and eosin (H&E). To estimate the extent of damage,
the specimen was observed under a light microscope.
LPS-induced inflammatory mortality in B6 mice
Male B6 mice weighing 18–22 g were pretreated with C12
(15 mg/kg) by i.v. injection 15 min before the i.v. injection of LPS
(20 mg/kg). Control animals received a similar volume (10 mL/kg)
of saline. Body weight change and mortality wererecorded for 7 days.
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Male ICR mice weighing 18–22 g were pretreated with
dexamethasone (5 mg/kg) or C12 (5 or 15 mg/kg) intraperitone-
ally. Control animals received a similar volume (200 mL/kg) of
saline. After 15 min, 200 mL of 10% azovan blue solution in saline
was i.v.-injected and 300 mL of acetic acid (0.7%) was i.p.-injected,
respectively. Then, 30 min after acetic acid injection, the
peritoneal fluid was collected in sterile and heparinized PBS
(1 mL) solution. The total of the collection was evaluated by
optical density assay (620 nm).
Carrageenan-induced paw oedema in mice
Male ICR mice weighing 18–22 g were divided into four groups
(n=6 in each), that were submitted with respect to the treatment
by the i.p. route with saline, Dexamethasone (5 mg/kg, Xianju
Pharma, Zhejiang, China) or C12 (5 or 15 mg/kg), 15 min before
oedema induction by subcutaneous injection of carrageenan
(300 mg/paw) in the right paw. The left paw was injected with
an equal volume of saline as a negative control, and both paws
were monitored by a procedure similar to that described elsewhere
[19]. The paw oedema was measured by a electronic micrometer




Abdominal constrictions to the i.p. injection of acetic acid
(0.6%) were monitored. The procedure was similar to that
previously described by de Campos et al. (18). Male ICR mice
weighing 18–22 g were pretreated with Dexamethasone (5 mg/kg)
or C12 (5 or 15 mg/kg) intraperitoneally 15 min before the
injection of acetic acid. Control animals received a similar volume
(10 mL/kg) of saline. After challenge, pairs of mice were placed in
separate boxes, and the number of abdominal constrictions was
cumulatively counted.
Formalin-induced inflammatory nociception in mice
The procedure used was similar to that previously described by
Correa and Calixto [30]. Male ICR mice weighing 18–22 g were
pretreated intraperitoneally with C12 (5 or 15 mg/kg) or
Dexamethasone (5 mg/kg) 15 min before pain induction. Control
animals received only saline. 20 mL of 2.5% formalin in PBS was
injected under the paw surface of the right hind paw. The mice
(control and treated groups) were observed simultaneously from 0–
30 min following formalin injection. The amount of time spent
licking the injected paw was timed with a chronometer and was
considered indicative of pain.
Statistical analysis
The results are presented as means6SD. The statistical
significance of differences between groups was obtained by means
of analysis of variance followed by the post-test of comparison. P
values less than 0.05 (p,0.05) were considered indicative of
significance. Nitrite determination and cell viability were per-
formed in triplicate. All experiments were repeated at least three
times.
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Figure S1 Toxicity assay of C12. Male ICR mice weighing
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